{"id":"vonoprazan-amoxicillin-tetracycline-14-days","safety":{"commonSideEffects":[{"rate":"10-30","effect":"Diarrhea"},{"rate":"5-15","effect":"Nausea"},{"rate":"5-10","effect":"Abdominal discomfort"},{"rate":"5-10","effect":"Headache"},{"rate":"1-5","effect":"Photosensitivity (tetracycline-related)"},{"rate":"1-3","effect":"Allergic reaction (amoxicillin-related)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Vonoprazan is a potassium-competitive acid blocker (PCAB) that inhibits the proton pump to reduce gastric acid, creating an environment where amoxicillin and tetracycline can effectively penetrate and kill H. pylori. Amoxicillin is a beta-lactam antibiotic that disrupts bacterial cell wall synthesis, while tetracycline inhibits bacterial protein synthesis. The combination is administered for 14 days as a standard triple-therapy regimen for H. pylori eradication.","oneSentence":"This triple-drug combination eradicates Helicobacter pylori by suppressing gastric acid (vonoprazan) while simultaneously attacking the bacteria with two antibiotics (amoxicillin and tetracycline).","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:15:48.367Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Helicobacter pylori infection eradication"}]},"trialDetails":[{"nctId":"NCT07333001","phase":"","title":"Efficacy and Safety of 7-day Triple Therapy Containing Amoxicillin and Tetracycline Versus 14-day Dual Therapy for Helicobacter Pylori Eradication","status":"COMPLETED","sponsor":"Yueyue Li","startDate":"2025-11-01","conditions":"HELICOBACTER PYLORI INFECTIONS","enrollment":508},{"nctId":"NCT07068607","phase":"PHASE4","title":"Efficacy Comparison of Vonoprazan Combined With Different Antibiotics in Dual Therapy for Helicobacter Pylori Eradication: A Prospective, Randomized Controlled Clinical Trial","status":"RECRUITING","sponsor":"Yongquan Shi","startDate":"2025-04-01","conditions":"Gastritis, Indigestion, Helicobacter Pylori Infection, Gastric Cancer, Peptic Ulcer","enrollment":400},{"nctId":"NCT06168084","phase":"PHASE4","title":"Helicobacter Rescue Therapy With Vonorazon and Amoxicillin Dual Therapy Versus Bismuth-containing Quadruple Therapy","status":"COMPLETED","sponsor":"Yongquan Shi","startDate":"2023-06-06","conditions":"Gastritis Dyspepsia Helicobacter Pylori Infection Gastric Cancer Peptic Ulcer","enrollment":688},{"nctId":"NCT06723197","phase":"PHASE4","title":"Efficacy of Different Durations of Dual and Quadruple Regimens for Helicobacter Pylori Eradication","status":"RECRUITING","sponsor":"Shandong University","startDate":"2024-12-10","conditions":"HELICOBACTER PYLORI INFECTIONS","enrollment":330},{"nctId":"NCT06299605","phase":"NA","title":"Triple Versus Quadruple Therapy for the Eradication of Helicobacter Pylori","status":"ENROLLING_BY_INVITATION","sponsor":"Shandong University","startDate":"2024-11-27","conditions":"Helicobacter Pylori Infection","enrollment":375},{"nctId":"NCT06168214","phase":"PHASE4","title":"Standard or Short-course Vonoprazan Non-bismuth Triple Therapy or High-dose Dual Therapy Versus Rabeprazole-bismuth Quadruple Therapy for Primary Helicobacter Pylori Eradication","status":"RECRUITING","sponsor":"Xijing Hospital of Digestive Diseases","startDate":"2023-09-04","conditions":"the Eradication Rates of Helicobacter Pylori","enrollment":1404},{"nctId":"NCT05049902","phase":"PHASE4","title":"Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication","status":"COMPLETED","sponsor":"Shandong University","startDate":"2021-09-21","conditions":"Helicobacter Pylori Infection","enrollment":1300},{"nctId":"NCT05173493","phase":"","title":"The Study About the Selection of Time for Retreatment of Helicobacter Pylori After Eradication Failure","status":"COMPLETED","sponsor":"Shandong University","startDate":"2021-12-30","conditions":"Helicobacter Pylori Infection","enrollment":670},{"nctId":"NCT05620602","phase":"","title":"The Effect of Time Intervals for Rescue Treatment on Eradication Effect of Helicobacter Pylori Infection","status":"UNKNOWN","sponsor":"Shandong University","startDate":"2022-11-11","conditions":"Helicobacter Pylori Infection","enrollment":628},{"nctId":"NCT04810793","phase":"","title":"The Study on the Selection of Time for Retreatment of Helicobacter Pylori After Eradication Failure","status":"COMPLETED","sponsor":"Shandong University","startDate":"2020-07-01","conditions":"Helicobacter Pylori","enrollment":820},{"nctId":"NCT05345210","phase":"PHASE4","title":"Vonoprazan Hp Dual or Triple Eradication Regimes","status":"UNKNOWN","sponsor":"Xijing Hospital of Digestive Diseases","startDate":"2022-04-25","conditions":"Helicobacter Pylori","enrollment":500},{"nctId":"NCT05126121","phase":"NA","title":"Efficacy and Safety of 14-day Concomitant Therapy for Difficult-to-Treat Helicobacter Pylori Infection","status":"UNKNOWN","sponsor":"Xiuli Zuo","startDate":"2021-11-20","conditions":"Helicobacter Pylori Infection","enrollment":60},{"nctId":"NCT05133193","phase":"NA","title":"Efficacy and Safety of 14-day Concomitant Therapy for Refractory Helicobacter Pylori Infection","status":"UNKNOWN","sponsor":"Shandong University","startDate":"2021-11-20","conditions":"Helicobacter Pylori Infection","enrollment":60},{"nctId":"NCT04991584","phase":"NA","title":"Efficacy and Safety of 14-day Concomitant Therapy for Helicobacter Pylori Infection","status":"UNKNOWN","sponsor":"Shandong University","startDate":"2021-08-04","conditions":"Helicobacter Pylori Infection","enrollment":60},{"nctId":"NCT04901117","phase":"PHASE4","title":"Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication: A Randomized Clinical Trial of 10 and 14 Days","status":"UNKNOWN","sponsor":"Shandong University","startDate":"2021-06","conditions":"Helicobacter Pylori Infection","enrollment":1300}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":939,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Vonoprazan+amoxicillin+tetracycline 14 days","genericName":"Vonoprazan+amoxicillin+tetracycline 14 days","companyName":"Xijing Hospital of Digestive Diseases","companyId":"xijing-hospital-of-digestive-diseases","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This triple-drug combination eradicates Helicobacter pylori by suppressing gastric acid (vonoprazan) while simultaneously attacking the bacteria with two antibiotics (amoxicillin and tetracycline). Used for Helicobacter pylori infection eradication.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}